Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Biogen to acquire TMS-007
July 2018
SHARING OPTIONS:

CAMBRIDGE, Mass.—June saw the beginning of an exclusive option agreement between Biogen and TMS Co. Ltd., under which Biogen will acquire TMS-007—a plasminogen activator with a novel mechanism of action that helps to break down blood clots and is thought to inhibit inflammation at the site of thrombosis—and backup compounds. Biogen will pay TMS $4 million up front and $18 million if Biogen exercises its option. TMS also stands to receive up to $335 million in potential development and commercialization milestones, as well as tiered royalties. TMS-007 has reduced infarct volume (dead tissue due to lack of blood supply) in rodent and primate models of embolic and thrombotic stroke. A double-blind, placebo-controlled Phase 2 study is underway to determine the safety and efficacy of a single intravenous administration up to 12 hours after stroke onset in patients with acute ischemic stroke.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.